Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

NCT01203618 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Trial terminated due to focus of primary therapeutic areas.

Conditions

Interventions

Sponsor

Morphotek